In-Vitro Diagnostics (IVD) Global Market - Forecast To 2028

September 2021 | 793 pages | ID: ICB8217C2C5EN
IQ4I Research & Consultancy Pvt. Ltd.

Abstracts

In-vitro diagnostic (IVD) are tests where reagents, instruments, and systems determine the state of health, to cure, mitigate, treat, or prevent disease. These tests can be performed on a variety of instruments such as small, handheld tests to complex laboratory instruments allowing doctors to diagnose patients effectively and decide to provide appropriate treatments.

According to IQ4I analysis, the In vitro diagnostic global market is expected to grow at low single digit CAGR from 2021 to 2028 to reach $96,485.2 million by 2028. The factors such as the growing incidence of chronic and infectious diseases, increasing adoption of point-of-care testing, the emergence of Next-generation molecular diagnostics, minimally invasive and non-invasive in-vitro diagnostics, rising number of CLIA-waived tests are driving the growth of the IVD market. However, the rising number of product recalls, lack of skilled laboratory technicians in developing nations, inadequate reimbursements, and stringent regulatory framework is expected to hamper the market growth.

The in-vitro diagnostics global market is segmented based on products, technology, applications, sample source, end-users and geography. The products market is segmented into instruments, reagents and software & services, where, reagents commanded the largest share of the market in 2021 and is expected to grow at low single digit CAGR from 2021 to 2028.

The IVD global market based on technology is segmented into immunochemistry, clinical chemistry, molecular diagnostics, clinical microbiology, hematology, coagulation and hemostasis and others. Among these, the immunochemistry segment commanded the largest share in 2021 and the market is expected to grow at low single digit CAGR from 2021 to 2028. The immunochemistry market is further sub-segmented based on techniques into Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Immunospot (Elispot) Assay, Radioimmunoassay (RIA), Rapid Tests, Chemiluminescence Immunoassay (CLIA), Fluoro Immunoassay (FIA), and Others. Among these, ELISA commanded the largest share in 2021; the rapid test segment occupied a significant share of the techniques market in 2021. The clinical chemistry market is sub-segmented based on technique into basic metabolic profile, electrolyte panel, liver panel, lipid profile, renal profile, thyroid function panel and others, among which, the basic metabolic profile commanded the largest share of the market in 2021, the lipid profile segment is expected to grow at a high single digit CAGR from 2021 to 2028. The molecular diagnostics market is further sub-segmented into PCR, microfluidics & microarray, INAAT, in-situ hybridization, NGS and others. Among these, the PCR segment generated the largest revenue in 2021, Microfluidics & microarray segment is expected to grow at early teen CAGR from 2021 to 2028.

The IVD global market based on application is segmented into oncology, diabetes, infectious diseases, genetic testing, cardiology, autoimmune diseases, drug testing, nephrology, transplantation, Blood & related disorders, and others, among them, the infectious disease segment commanded the largest revenue in 2021, the transplantation segment is expected to grow at high double digit CAGR from 2021 to 2028. The oncology market is further sub-segmented based on cancer types into lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer and others, among which, colorectal cancer commanded the largest share in 2021 and the market is expected to grow at a high single digit CAGR from 2021 to 2028. The oncology market based on cancer care is further sub-segmented into diagnosis, early screening, companion diagnostics, prognosis and recurrence monitoring, where, diagnosis commanded the largest share of the market in 2021, the companion diagnostics segment is expected to grow at high single digit CAGR from 2021 to 2028. The infectious disease market is further sub-segment into bacterial, viral infection, fungal and others among which the viral infection commanded the largest share of the market in 2021. The bacterial infection global market is further segmented based on infection agent into Treponema pallidum, Gardnerella, Staphylococcus aureus, Clostridium difficile, Streptococcus (A&B), Methicillin-resistant Staphylococcus aureus (MRSA), Chlamydia trachomatis (CT) & Neisseria gonorrhea (NG) and tuberculosis (TB) and others. Among these, Staphylococcus aureus commanded the largest revenue in 2021. The MRSA segment is expected to grow at low single digit CAGR from 2021 to 2028. The Viral infection global market is segmented based on the type of infection into HIV-1, influenza, dengue, Hepatitis B, Hepatitis C, Human papillomavirus (HPV), herpes simplex virus (HSC), zika virus, and COVID & others. Among these, the COVID & others segment contributed the largest share of the market in 2021, HIV-1 segment is expected to grow at a double digit CAGR from 2021 to 2028. The Fungal infection global market based on the type of infection is segmented into Candida, Aspergillus, and others. Among these, Candida commanded the largest revenue in 2021. The other infections segment is further sub-segmented into malaria, trichomonas vaginalis and others, among this, Trichomonas vaginalis commanded the largest share in 2021, and malaria is expected to grow at low single digit CAGR from 2021 to 2028.

The IVD global market based on sample source is segmented into blood, urine, mucus and others, among which blood commanded the largest share of the market in 2021, and is expected to grow at mid single digit CAGR from 2021 to 2028. The blood-based tests provide accurate results when compare to other sources, and, they are suitable sample sources for early diagnosis before the occurrence of symptoms.

The In-vitro diagnostics end-user market is segmented into diagnostic laboratories, hospitals, academics and research centers, homecare and other end-users. The hospitals' segment accounted for the largest revenue in 2021 and is estimated to grow at low single digit CAGR from 2021 to 2028 due to the availability of advanced and novel technologies for the diagnosis and also the availability of skilled professionals with more capital investments.

Geographical-wise, the North America region commanded the largest revenue in 2021 owing to the high demand for early detection, treatment and prevention tests with advanced technology. However, the Asia-Pacific region is expected to grow at mid single digit CAGR from 2021 to 2028 with increasing awareness for the highly precise, rapid and advanced tests for a better outcome.

The in-vitro diagnostics global market is competitive and all the active players in this market are involved in innovating new and advanced products to maintain their market shares. The key players in the IVD global market include Abbott Laboratories, Inc. (U.S.), F.Hoffmann-La Roche AG (Switzerland), Siemens Healthineers(Germany), Biomerieux SA (France), Becton Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), Sysmex (Japan), Dexcom (U.S), Hologic (U.S), Quidel (U.S) Qiagen N.V. (the Netherlands) and Thermo Fisher Scientific, Inc. (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Contents

1 EXECUTIVE SUMMARY

2 INTRODUCTION

2.1 KEY TAKE AWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
  2.6.1 MARKET SIZE ESTIMATION
  2.6.2 MARKET BREAKDOWN & DATA TRIANGULATION
  2.6.3 SECONDARY SOURCES
  2.6.4 PRIMARY SOURCES
  2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
  2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
  2.6.7 ASSUMPTIONS

3 MARKET ANALYSIS

3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
  3.3.1 DRIVERS AND OPPORTUNITIES
    3.3.1.1 Growing incidence of chronic and infectious diseases
    3.3.1.2 Increase in demand for IVD tests due to COVID-19 pandemic
    3.3.1.3 Increasing adoption of point-of-care testing
    3.3.1.4 The emergence of next-generation molecular diagnostics
    3.3.1.5 Growing awareness of companion diagnostics and personalized medicine
    3.3.1.6 The emergence of minimally invasive and non-invasive diagnostics
    3.3.1.7 Rising number of CLIA-waived IVD tests
  3.3.2 RESTRAINTS & THREATS
    3.3.2.1 Rising incidence of product recalls
    3.3.2.2 Lack of skilled laboratory technicians in developing nations
    3.3.2.3 Inadequate reimbursement
    3.3.2.4 Stringent regulatory framework
3.4 PORTER’S FIVE FORCE ANALYSIS
  3.4.1 THREAT OF NEW ENTRANTS
  3.4.2 THREAT OF SUBSTITUTES
  3.4.3 COMPETITIVE RIVALRY
  3.4.4 BARGAINING POWER OF SUPPLIERS
  3.4.5 BARGAINING POWER OF BUYERS
3.5 REGULATORY AFFAIRS
  3.5.1 U.S.A
  3.5.2 EUROPE
  3.5.3 CHINA
  3.5.4 INDIA
  3.5.5 JAPAN
  3.5.6 AUSTRALIA
  3.5.7 SOUTH KOREA
3.6 TECHNOLOGICAL ADVANCEMENTS
3.7 FUNDING SCENARIO
3.8 MERGERS & ACQUISITIONS
3.9 SUPPLY CHAIN ANALYSIS
3.10 IMPACT OF COVID-19
3.11 CLINICAL TRIALS
  3.11.1 CFDNA CLINICALTRIALS
  3.11.2 CIRCULATING TUMOR CELLS (CTC)
  3.11.3 COMPANION DIAGNOSTICS
  3.11.4 IMMUNOASSAYS
  3.11.5 LIPID PROFILE
  3.11.6 MICROARRAY
  3.11.7 GENETIC DISEASES
3.12 MARKET SHARE ANALYSIS BY IN-VITRO DIAGNOSTICS MAJOR PLAYERS
  3.12.1 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
  3.12.2 IMMUNOCHEMISTRY GLOBAL MARKET SHARE ANALYSIS
  3.12.3 CLINICAL CHEMISTRY GLOBAL MARKET SHARE ANALYSIS
  3.12.4 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
  3.12.5 CLINICAL MICROBIOLOGY GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS
  3.12.6 HEMATOLOGY GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS
  3.12.7 COAGULATION AND HEMOSTASIS MARKET SHARE ANALYSIS BY MAJOR PLAYERS

4 IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY PRODUCT

4.1 INTRODUCTION
4.2 INSTRUMENTS
4.3 REAGENTS
4.4 SOFTWARE AND SERVICES

5 IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY TECHNOLOGY

5.1 INTRODUCTION
5.2 IMMUNOCHEMISTRY
  5.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
  5.2.2 ENZYME-LINKED IMMUNOSPOT (ELISPOT) ASSAY
  5.2.3 RADIOIMMUNOASSAY (RIA)
  5.2.4 RAPID TESTS
  5.2.5 CHEMILUMINESCENCE IMMUNOASSAYS (CLIA)
  5.2.6 FLUORESCENCE IMMUNOASSAYS (FIA)
  5.2.7 OTHER IMMUNOASSAYS
5.3 CLINICAL CHEMISTRY
  5.3.1 BASIC METABOLIC PROFILE
  5.3.2 ELECTROLYTE PANEL
  5.3.3 LIVER PANEL
  5.3.4 LIPID PANEL
  5.3.5 RENAL PANEL
  5.3.6 THYROID FUNCTION PANEL
  5.3.7 OTHERS (CLINICAL CHEMISTRY TESTS)
5.4 MOLECULAR DIAGNOSTICS (MDX)
  5.4.1 PCR (POLYMERASE CHAIN REACTION)
  5.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
  5.4.3 MICROFLUIDICS & MICROARRAY
  5.4.4 IN SITU HYBRIDIZATION (ISH)
  5.4.5 NEXT-GENERATION SEQUENCING (NGS)
  5.4.6 OTHER MDX TECHNOLOGIES
5.5 CLINICAL MICROBIOLOGY
5.6 HEMATOLOGY
5.7 COAGULATION AND HEMOSTASIS
5.8 OTHERS

6 IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY APPLICATION

6.1 INTRODUCTION
6.2 ONCOLOGY
  6.2.1 CANCER TYPES
    6.2.1.1 Introduction
    6.2.1.2 Lung Cancer
    6.2.1.3 Breast Cancer
    6.2.1.4 Colorectal Cancer
    6.2.1.5 Prostate Cancer
    6.2.1.6 Melanoma
    6.2.1.7 Ovarian Cancer
    6.2.1.8 Others
  6.2.2 CANCER CARE
    6.2.2.1 Introduction
    6.2.2.2 Diagnosis
    6.2.2.3 Early Screening
    6.2.2.4 Companion Diagnostics
    6.2.2.5 Prognosis Monitoring
    6.2.2.6 Recurrence Monitoring
6.3 DIABETES
6.4 INFECTIOUS DISEASES
  6.4.1 BACTERIAL INFECTION
    6.4.1.1 Treponema pallidum
    6.4.1.2 Gardnerella vaginalis
    6.4.1.3 Staphylococcus aureus
    6.4.1.4 Clostridium difficile
    6.4.1.5 Streptococcus (A & B)
    6.4.1.6 Methicillin-Resistant Staphylococcus Aureus (MRSA)
    6.4.1.7 Chlamydia trachomatis (CT) And Neisseria gonorrhoeae (NG)
    6.4.1.8 Tuberculosis (TB)
    6.4.1.9 Other Bacterial Infection
  6.4.2 VIRAL INFECTION
    6.4.2.1 HIV-1
    6.4.2.2 Influenza
    6.4.2.3 Dengue
    6.4.2.4 Hepatitis B
    6.4.2.5 Hepatitis C
    6.4.2.6 Human Papilloma Virus (HPV)
    6.4.2.7 Herpes Simplex Virus (HSV)
    6.4.2.8 Zika Virus
    6.4.2.9 COVID and Other Viral Infection
  6.4.3 FUNGAL INFECTION
    6.4.3.1 Candida
    6.4.3.2 Aspergillus
    6.4.3.3 Other Fungal Infection
  6.4.4 OTHER INFECTION
    6.4.4.1 Malaria
    6.4.4.2 Trichomonas vaginalis
    6.4.4.3 Other Infections
6.5 GENETIC TESTING
6.6 CARDIOLOGY DISEASES
6.7 AUTOIMMUNE DISEASES
6.8 DRUG TESTING
6.9 NEPHROLOGY
6.10 TRANSPLANTATION
6.11 BLOOD AND RELATED DISORDERS
6.12 OTHER DISEASES

7 IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE

7.1 INTRODUCTION
7.2 BLOOD
7.3 MUCUS
7.4 URINE
7.5 OTHERS

8 IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY END-USER

8.1 INTRODUCTION
8.2 DIAGNOSTIC LABORATORIES
8.3 HOSPITALS
8.4 ACADEMIC & RESEARCH CENTRES
8.5 HOME CARE
8.6 OTHER END-USERS

9 REGIONAL MARKET ANALYSIS

9.1 INTRODUCTION
9.2 NORTH AMERICA
  9.2.1 U.S.
  9.2.2 REST OF NORTH AMERICA
9.3 EUROPE
  9.3.1 GERMANY
  9.3.2 U.K.
  9.3.3 FRANCE
  9.3.4 REST OF E.U.
9.4 ASIA PACIFIC
  9.4.1 JAPAN
  9.4.2 CHINA
  9.4.3 INDIA
  9.4.4 REST OF APAC
9.5 REST OF THE WORLD
  9.5.1 BRAZIL
  9.5.2 REST OF LATIN AMERICA
  9.5.3 MIDDLE EAST AND OTHERS

10 COMPANY DEVELOPMENTS

10.1 INTRODUCTION
  10.1.1 REGULATORY APPROVAL AS A MAJOR GROWTH STRATEGY OF IN-VITRO DIAGNOSTICS MARKET PLAYERS
10.2 APPROVAL
10.3 NEW PRODUCT LAUNCH
10.4 AGREEMENTS PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
10.5 MERGERS AND ACQUISITIONS
10.6 BUSINESS EXPANSION

11 COMPANY PROFILES

11.1 ABBOTT LABORATORIES
  11.1.1 OVERVIEW
  11.1.2 FINANCIALS
  11.1.3 PRODUCT PORTFOLIO
  11.1.4 KEY DEVELOPMENTS
  11.1.5 BUSINESS STRATEGY
  11.1.6 SWOT ANALYSIS
11.2 BIOMERIEUX
  11.2.1 OVERVIEW
  11.2.2 FINANCIALS
  11.2.3 PRODUCT PORTFOLIO
  11.2.4 KEY DEVELOPMENTS
  11.2.5 BUSINESS STRATEGY
  11.2.6 SWOT ANALYSIS
11.3 DANAHER CORPORATION
  11.3.1 OVERVIEW
  11.3.2 FINANCIALS
  11.3.3 PRODUCT PORTFOLIO
  11.3.4 KEY DEVELOPMENTS
  11.3.5 BUSINESS STRATEGY
  11.3.6 SWOT ANALYSIS
11.4 DEXCOM, INC.
  11.4.1 OVERVIEW
  11.4.2 FINANCIALS
  11.4.3 PRODUCT PORTFOLIO
  11.4.4 KEY DEVELOPMENTS
  11.4.5 BUSINESS STRATEGY
  11.4.6 SWOT ANALYSIS
11.5 F. HOFFMANN LA ROCHE
  11.5.1 OVERVIEW
  11.5.2 FINANCIALS
  11.5.3 PRODUCT PORTFOLIO
  11.5.4 KEY DEVELOPMENTS
  11.5.5 BUSINESS STRATEGY
  11.5.6 SWOT ANALYSIS
11.6 HOLOGIC, INC.
  11.6.1 OVERVIEW
  11.6.2 FINANCIALS
  11.6.3 PRODUCT PORTFOLIO
  11.6.4 KEY DEVELOPMENTS
  11.6.5 BUSINESS STRATEGY
  11.6.6 SWOT ANALYSIS
11.7 QUIDEL CORPORATION
  11.7.1 OVERVIEW
  11.7.2 FINANCIALS
  11.7.3 PRODUCT PORTFOLIO
  11.7.4 KEY DEVELOPMENTS
  11.7.5 BUSINESS STRATEGY
  11.7.6 SWOT ANALYSIS
11.8 SIEMENS HEALTHINEERS
  11.8.1 OVERVIEW
  11.8.2 FINANCIALS
  11.8.3 PRODUCT PORTFOLIO
  11.8.4 KEY DEVELOPMENTS
  11.8.5 BUSINESS STRATEGY
  11.8.6 SWOT ANALYSIS
11.9 SYSMEX
  11.9.1 OVERVIEW
  11.9.2 FINANCIALS
  11.9.3 PRODUCT PORTFOLIO
  11.9.4 KEY DEVELOPMENTS
  11.9.5 BUSINESS STRATEGY
  11.9.6 SWOT ANALYSIS
11.10 THERMO FISHER SCIENTIFIC
  11.10.1 OVERVIEW
  11.10.2 FINANCIALS
  11.10.3 PRODUCT PORTFOLIO
  11.10.4 KEY DEVELOPMENTS
  11.10.5 BUSINESS STRATEGY
  11.10.6 SWOT ANALYSIS

List Of Tables

LIST OF TABLES

TABLE 1 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 2 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCT (2020-2028) ($MN)
TABLE 3 IN-VITRO DIAGNOSTICS INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
TABLE 4 IN-VITRO DIAGNOSTICS REAGENTS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 5 IN-VITRO DIAGNOSTICS SOFTWARE AND SERVICES GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
TABLE 6 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2020-2028) ($MN)
TABLE 7 IMMUNOCHEMISTRY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 8 IMMUNOCHEMISTRY GLOBAL MARKET REVENUE, BY TECHNIQUE (2020-2028) ($MN)
TABLE 9 ELISA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 10 ELISPOT GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
TABLE 11 RADIOIMMUNOASSAY (RIA) GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
TABLE 12 RAPID TESTS GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
TABLE 13 CHEMILUMINESCENCE IMMUNOASSAYS (CLIA) GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 14 FLUORESCENCE IMMUNOASSAYS (FIA) GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 15 OTHER IMMUNOASSAYS GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
TABLE 16 CLINICAL CHEMISTRY GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
TABLE 17 CLINICAL CHEMISTRY GLOBAL MARKET REVENUE, BY TECHNIQUE (2020-2028) ($MN)
TABLE 18 BASIC METABOLIC PROFILE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 19 ELECTROLYTE PANEL GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 20 LIVER PANEL GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 21 LIPID PANEL GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
TABLE 22 RENAL PROFILE GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
TABLE 23 THYROID FUNCTION PANEL GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
TABLE 24 OTHER GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
TABLE 25 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 26 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNIQUE (2020-2028) ($MN)
TABLE 27 PCR GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 28 INAAT GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 29 MICROFLUIDICS & MICROARRAY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 30 IN SITU HYBRIDIZATION GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 31 NGS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 32 OTHER MDX TECHNOLOGIES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 33 CLINICAL MICROBIOLOGY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 34 HEMATOLOGY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 35 COAGULATION AND HEMOSTASIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 36 OTHER TECHNOLOGIES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 37 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION (2020-2028) ($MN)
TABLE 38 ONCOLOGY GLOBAL MARKET REVENUE, BY CANCER TYPE, (2020-2028) ($MN)
TABLE 39 ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 40 LUNG CANCER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 41 BREAST CANCER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 42 COLORECTAL CANCER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 43 PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 44 MELANOMA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 45 OVARIAN CANCER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 46 OTHER CANCERS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 47 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY CANCER CARE, (2020-2028) ($MN)
TABLE 48 DIAGNOSIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 49 EARLY SCREENING GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 50 COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 51 PROGNOSIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 52 RECURRENCE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 53 DIABETES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 54 INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
TABLE 55 INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 56 BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY INFECTION (2020-2028) ($MN)
TABLE 57 BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 58 TREPONEMA PALLIDUM GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 59 GARDNERELLA VAGINALIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 60 S. AUREUS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 61 CLOSTRIDIUM DIFFICILE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 62 STREPTOCOCCUS (A & B) GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 63 MRSA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 64 CT/NG GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 65 TUBERCULOSIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 66 OTHER BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 67 VIRAL INFECTION GLOBAL MARKET REVENUE, BY TYPE OF INFECTION (2020-2028) ($MN)
TABLE 68 VIRAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 69 HIV-1 GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 70 INFLUENZA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 71 DENGUE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 72 HEPATITIS B GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 73 HEPATITIS C GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 74 HPV GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 75 HSV GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 76 ZIKA VIRUS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 77 COVID AND OTHER VIRUSES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 78 FUNGAL INFECTION GLOBAL MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 79 FUNGAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 80 CANDIDA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 81 ASPERGILLUS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 82 OTHER FUNGAL GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 83 OTHER INFECTIONS GLOBAL MARKET REVENUE, BY TYPE, (2020-2028) ($MN)
TABLE 84 MALARIA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 85 TRICHOMONAS VAGINALIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 86 OTHER INFECTIONS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 87 GENETIC TESTING GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 88 CARDIOLOGY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 89 AUTOIMMUNE DISEASES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 90 DRUG TESTING GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 91 NEPHROLOGY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 92 TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 93 BLOOD AND RELATED DISORDER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 94 OTHER DISEASES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 95 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY SAMPLE SOURCE, (2020-2028) ($MN)
TABLE 96 BLOOD SAMPLE SOURCE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 97 MUCUS SAMPLE SOURCE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 98 URINE SAMPLE SOURCE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 99 OTHER SAMPLE SOURCE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 100 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS, (2020-2028) ($MN)
TABLE 101 DIAGNOSTIC LABORATORIES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 102 HOSPITALS END-USER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 103 ACADEMICS AND RESEARCH CENTERS END-USER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 104 HOME CARE END-USERS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 105 OTHER END USERS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 106 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
TABLE 107 NORTH AMERICA IVD MARKET REVENUE, BY PRODUCT, (2020-2028) ($MN)
TABLE 108 NORTH AMERICA IVD MARKET REVENUE, BY TECHNOLOGY, (2020-2028) ($MN)
TABLE 109 NORTH AMERICA IMMUNOCHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
TABLE 110 NORTH AMERICA CLINICAL CHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
TABLE 111 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
TABLE 112 NORTH AMERICA IVD MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
TABLE 113 NORTH AMERICA ONCOLOGY MARKET REVENUE, BY CANCER TYPE, (2020-2028) ($MN)
TABLE 114 NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE, (2020-2028) ($MN)
TABLE 115 NORTH AMERICA INFECTIOUS DISEASES MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
TABLE 116 NORTH AMERICA BACTERIAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 117 NORTH AMERICA VIRAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 118 NORTH AMERICA FUNGAL INFECTION MARKET REVENUE, BY INFECTION, (2020-2028) ($MN)
TABLE 119 NORTH AMERICA OTHER INFECTIONS MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 120 NORTH AMERICA IVD MARKET REVENUE, BY SAMPLE SOURCE, (2020-2028) ($MN)
TABLE 121 NORTH AMERICA IVD MARKET REVENUE, BY END USERS, (2020-2028) ($MN)
TABLE 122 NORTH AMERICA IVD MARKET REVENUE, BY COUNTRY, (2020-2028) ($MN)
TABLE 123 EUROPE IVD MARKET REVENUE, BY PRODUCT, (2020-2028) ($MN)
TABLE 124 EUROPE IVD MARKET REVENUE, BY TECHNOLOGY, (2020-2028) ($MN)
TABLE 125 EUROPE IMMUNOCHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
TABLE 126 EUROPE CLINICAL CHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
TABLE 127 EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
TABLE 128 EUROPE IVD MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
TABLE 129 EUROPE ONCOLOGY MARKET REVENUE, BY CANCER TYPE, (2020-2028) ($MN)
TABLE 130 EUROPE ONCOLOGY MARKET REVENUE, BY CANCER CARE, (2020-2028) ($MN)
TABLE 131 EUROPE INFECTIOUS DISEASES MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
TABLE 132 EUROPE BACTERIAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 133 EUROPE VIRAL INFECTION MARKET REVENUE, BY INFECTION, (2020-2028) ($MN)
TABLE 134 EUROPE FUNGAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 135 EUROPE OTHER INFECTIONS MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 136 EUROPE IVD MARKET REVENUE, BY SAMPLE SOURCE, (2020-2028) ($MN)
TABLE 137 EUROPE IVD MARKET REVENUE, BY END USERS, (2020-2028) ($MN)
TABLE 138 EUROPE IVD MARKET REVENUE, BY COUNTRY, (2020-2028) ($MN)
TABLE 139 APAC IVD MARKET REVENUE, BY PRODUCT, (2020-2028) ($MN)
TABLE 140 APAC IVD MARKET REVENUE, BY TECHNOLOGY, (2020-2028) ($MN)
TABLE 141 APAC IMMUNOCHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
TABLE 142 APAC CLINICAL CHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
TABLE 143 APAC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
TABLE 144 APAC IVD MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
TABLE 145 APAC ONCOLOGY MARKET REVENUE, BY CANCER TYPE, (2020-2028) ($MN)
TABLE 146 APAC ONCOLOGY MARKET REVENUE, BY CANCER CARE, (2020-2028) ($MN)
TABLE 147 APAC INFECTIOUS DISEASES MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
TABLE 148 APAC BACTERIAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 149 APAC VIRAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 150 APAC FUNGAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 151 APAC OTHER INFECTIONS MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 152 APAC IVD MARKET REVENUE, BY SAMPLE SOURCE, (2020-2028) ($MN)
TABLE 153 APAC IVD MARKET REVENUE, BY END USERS, (2020-2028) ($MN)
TABLE 154 APAC IVD MARKET REVENUE, BY COUNTRY, (2020-2028) ($MN)
TABLE 155 ROW IVD MARKET REVENUE, BY PRODUCT, (2020-2028) ($MN)
TABLE 156 ROW IVD MARKET REVENUE, BY TECHNOLOGY, (2020-2028) ($MN)
TABLE 157 ROW IMMUNOCHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
TABLE 158 ROW CLINICAL CHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
TABLE 159 ROW MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
TABLE 160 ROW IVD MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
TABLE 161 ROW ONCOLOGY MARKET REVENUE, BY CANCER TYPE, (2020-2028) ($MN)
TABLE 162 ROW CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE, (2020-2028) ($MN)
TABLE 163 ROW INFECTIOUS DISEASES MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
TABLE 164 ROW BACTERIAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 165 ROW VIRAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 166 ROW FUNGAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 167 ROW OTHER INFECTIONS MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
TABLE 168 ROW IVD MARKET REVENUE, BY SAMPLE SOURCE, (2020-2028) ($MN)
TABLE 169 ROW IVD MARKET REVENUE, BY END USERS, (2020-2028) ($MN)
TABLE 170 ROW IVD MARKET REVENUE, BY COUNTRY, (2020-2028) ($MN)
TABLE 171 APPROVALS (2020-2021)
TABLE 172 NEW PRODUCT LAUNCH (2020-2021)
TABLE 173 COLLABORATIONS (2020-2021)
TABLE 174 MERGERS AND ACQUISITIONS (2020-2021)
TABLE 175 BUSINESS EXPANSION (2020-2021)
TABLE 176 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
TABLE 177 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2019-2021)(Q2) ($MN)
TABLE 178 ABBOTT LABORATORIES: DIAGNOSTICS, BY SUB-SEGMENT, (2019-2021) (Q2) ($MN)
TABLE 179 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)
TABLE 180 BIOMERIEUX: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
TABLE 181 BIOMERIEUX: TOTAL REVENUE, BY SEGMENTS, (2019-2021)(Q2) ($MN)
TABLE 182 BIOMERIEUX: TOTAL REVENUE, BY SUB SEGMENTS, (2019-2021)(Q2) ($MN)
TABLE 183 BIOMERIEUX: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)
TABLE 184 DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
TABLE 185 DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q2) ($MN)
TABLE 186 DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)
TABLE 187 DEXCOM, INC: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q2) ($MN)
TABLE 188 DEXCOM, INC: TOTAL REVENUE, BY SEGMENT (2019-2021)(Q2) ($MN)
TABLE 189 DEXCOM, INC: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q2) ($MN)
TABLE 190 F. HOFFMANN LA ROCHE: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
TABLE 191 F. HOFFMANN LA ROCHE: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q2) ($MN)
TABLE 192 F. HOFFMANN LA ROCHE: DIAGNOSTICS, BY DIAGNOSTICS SUB-SEGMENT, (2019-2021) (Q2) ($MN)
TABLE 193 HOFFMANN LA ROCHE: DIAGNOSTICS DIVISION TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)
TABLE 194 HOLOGIC: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
TABLE 195 HOLOGIC: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q2) ($MN)
TABLE 196 HOLOGIC: DIAGNOSTICS, SUB SEGMENTS, (2019-2021) (Q2) ($MN)
TABLE 197 HOLOGIC: TOTAL REVENUE, BY GEOGRAPHY, (2020-2021) (Q2) ($MN)
TABLE 198 QUIDEL CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
TABLE 199 QUIDEL CORPORATION: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q2) ($MN)
TABLE 200 QUIDEL CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)
TABLE 201 SIEMENS HEALTHINEERS: TOTAL REVENUE AND R&D EXPENSES, (2019- 2021) (Q2) ($MN)
TABLE 202 SIEMENS HEALTHINEERS: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q2) ($MN)
TABLE 203 SIEMENS HEALTHINEERS: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)
TABLE 204 SYSMEX: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q1) ($MN)
TABLE 205 SYSMEX: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q1) ($MN)
TABLE 206 THERMO FISHER SCIENTIFIC: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
TABLE 207 THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q2) ($MN)
TABLE 208 THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)

List Of Figures

LIST OF FIGURES

FIGURE 1 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION (2020-2028) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: IN-VITRO DIAGNOSTICS GLOBAL MARKET
FIGURE 3 IN-VITRO DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 IN-VITRO DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 IN-VITRO DIAGNOSTICS GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 6 IVD MARKET SEGMENTATION
FIGURE 7 IVD TECHNOLOGY MARKET SUB-SEGMENTS
FIGURE 8 IVD APPLICATION MARKET SUB-SEGMENTS
FIGURE 9 MARKET DYNAMICS
FIGURE 10 IN-VITRO DIAGNOSTICS GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 11 IN-VITRO DIAGNOSTICS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 12 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021 (%)
FIGURE 13 IMMUNOCHEMISTRY GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021 (%)
FIGURE 14 CLINICAL CHEMISTRY GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021 (%)
FIGURE 15 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021 (%)
FIGURE 16 CLINICAL MICROBIOLOGY GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021
FIGURE 17 HEMATOLOGY GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021 (%)
FIGURE 18 COAGULATION AND HEMOSTASIS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021 (%)
FIGURE 19 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY PRODUCT, (2021 V/S 2028) (%)
FIGURE 20 IN-VITRO DIAGNOSTICS INSTRUMENTS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 21 IN-VITRO DIAGNOSTICS REAGENTS MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 22 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY, (2021) CAGR (%)
FIGURE 23 IMMUNOCHEMISTRY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 24 IMMUNOCHEMISTRY GLOBAL MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 25 ELISA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 26 ELISPOT GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 27 RIA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 28 RAPID TESTS GLOBAL MARKET SHARE, BY REGION (2021 V/S 2028) (%)
FIGURE 29 CLIA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 30 FIA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 31 OTHER IMMUNOASSAYS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 32 CLINICAL CHEMISTRY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 33 CLINICAL CHEMISTRY GLOBAL MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 34 BASIC METABOLIC PROFILE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 35 ELECTROLYTE PANEL GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 36 LIVER PANEL GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 37 LIPID PANEL GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 38 RENAL PROFILE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 39 RENAL PROFILE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 40 OTHERS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 41 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 42 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 43 PCR GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 44 INAAT GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 45 MICROFLUIDICS & MICROARRAY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 46 IN SITU HYBRIDIZATION GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 47 NGS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 48 OTHER MDX TECHNOLOGIES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 49 CLINICAL MICROBIOLOGY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 50 HEMATOLOGY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 51 COAGULATION AND HEMOSTASIS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 52 OTHER TECHNOLOGIES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 53 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
FIGURE 54 ONCOLOGY GLOBAL MARKET SHARE, BY CANCER TYPE, (2021 V/S 2028)(%)
FIGURE 55 COLORECTAL CANCER GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 56 OTHERS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 57 CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY CANCER CARE, (2021 V/S 2028) (%)
FIGURE 58 EARLY SCREENING GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 59 DIABETES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 60 INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
FIGURE 61 INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 62 BACTERIAL INFECTION GLOBAL MARKET SHARE, BY INFECTION, (2021) (%) (CAGR)
FIGURE 63 TREPONEMA PALLIDUM GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 64 S. AUREUS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 65 CLOSTRIDIUM DIFFICILE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 66 STREPTOCOCCUS (A & B) GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 67 MRSA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 68 CT/NG GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 69 TUBERCULOSIS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 70 OTHER BACTERIAL INFECTION GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 71 VIRAL INFECTIONS GLOBAL MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 72 VIRAL INFECTION GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 73 HIV-1 GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 74 INFLUENZA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 75 DENGUE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 76 HEPATITIS B GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 77 HPV GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 78 HSV GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 79 ZIKA VIRUS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 80 COVID AND OTHER VIRUSES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 81 FUNGAL INFECTION GLOBAL MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 82 OTHER INFECTIONS GLOBAL MARKET SHARE, BY TYPE, (2021 V/S 2028) (%)
FIGURE 83 MALARIA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 84 TRICHOMONAS VAGINALIS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 85 OTHER INFECTIONS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 86 GENETIC TESTING GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 87 CARDIOLOGY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 88 AUTOIMMUNE DISEASES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 89 DRUG TESTING GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 90 NEPHROLOGY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 91 TRANSPLANTATION GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 92 BLOOD AND RELATED DISORDER GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 93 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY SAMPLE SOURCE, (2021 V/S 2028) (%)
FIGURE 94 BLOOD SAMPLE SOURCE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 95 URINE SAMPLE SOURCE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 96 OTHER SAMPLE SOURCE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 97 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY END-USERS, (2021 V/S 2028) (%)
FIGURE 98 DIAGNOSTIC LABORATORIES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 99 HOSPITALS END-USER GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 100 ACADEMICS AND RESEARCH CENTERS END-USER GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 101 HOME CARE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
FIGURE 102 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
FIGURE 103 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION AND COUNTRY, (2021) ($MN)
FIGURE 104 NORTH AMERICA IVD MARKET SHARE, BY PRODUCT, (2021 V/S 2028) (%)
FIGURE 105 NORTH AMERICA IVD MARKET SHARE, BY TECHNOLOGY, (2021 V/S 2028) (%)
FIGURE 106 NORTH AMERICA IMMUNOCHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 107 NORTH AMERICA CLINICAL CHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 108 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 109 NORTH AMERICA IVD MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
FIGURE 110 NORTH AMERICA ONCOLOGY MARKET SHARE, BY CANCER TYPE, (2021) (%)
FIGURE 111 NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE, BY CANCER CARE, (2021 V/S 2028) (%)
FIGURE 112 NORTH AMERICA INFECTIOUS DISEASES MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
FIGURE 113 NORTH AMERICA BACTERIAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 114 NORTH AMERICA VIRAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 115 NORTH AMERICA FUNGAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 116 NORTH AMERICA OTHER INFECTIONS MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 117 NORTH AMERICA IVD MARKET SHARE, BY SAMPLE SOURCE, (2021 V/S 2028) (%)
FIGURE 118 NORTH AMERICA IVD MARKET SHARE, BY END-USERS, (2021 V/S 2028) (%)
FIGURE 119 NORTH AMERICA IVD MARKET SHARE, BY COUNTRY, (2021 V/S 2028) (%)
FIGURE 120 U.S. IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
FIGURE 121 U.S. IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
FIGURE 122 U.S. IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
FIGURE 123 REST OF N.A. IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
FIGURE 124 REST OF N.A. IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
FIGURE 125 REST OF N.A. IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
FIGURE 126 EUROPE IVD MARKET SHARE, BY PRODUCT, (2021 V/S 2028) (%)
FIGURE 127 EUROPE IVD MARKET SHARE, BY TECHNOLOGY, (2021 V/S 2028) (%)
FIGURE 128 EUROPE IMMUNOCHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 129 EUROPE CLINICAL CHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 130 EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 131 EUROPE IVD MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
FIGURE 132 EUROPE ONCOLOGY MARKET SHARE, BY CANCER TYPE, (2021) (%)
FIGURE 133 EUROPE ONCOLOGY MARKET SHARE, BY CANCER CARE, (2021 V/S 2028) (%)
FIGURE 134 EUROPE INFECTIOUS DISEASES MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
FIGURE 135 EUROPE BACTERIAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 136 EUROPE VIRAL INFECTION MARKET SHARE, BY INFECTION, (2021 V/S 2028) (%)
FIGURE 137 EUROPE FUNGAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 138 EUROPE OTHER INFECTIONS MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 139 EUROPE IVD MARKET SHARE, BY SAMPLE SOURCE, (2021 V/S 2028) (%)
FIGURE 140 EUROPE IVD MARKET SHARE, BY END-USERS, (2021 V/S 2028) (%)
FIGURE 141 EUROPE IVD MARKET SHARE, BY COUNTRY, (2021 V/S 2028) (%)
FIGURE 142 GERMANY IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
FIGURE 143 GERMANY IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
FIGURE 144 GERMANY IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
FIGURE 145 U.K. IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
FIGURE 146 U.K. IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
FIGURE 147 U.K. IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
FIGURE 148 FRANCE IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
FIGURE 149 FRANCE IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
FIGURE 150 FRANCE IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
FIGURE 151 REST OF E.U. IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
FIGURE 152 REST OF E.U. IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
FIGURE 153 REST OF E.U. IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
FIGURE 154 APAC IVD MARKET SHARE, BY PRODUCT, (2021 V/S 2028) (%)
FIGURE 155 APAC IVD MARKET SHARE, BY TECHNOLOGY, (2021 V/S 2028) (%)
FIGURE 156 APAC IMMUNOCHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 157 APAC CLINICAL CHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 158 APAC MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 159 APAC IVD MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
FIGURE 160 APAC ONCOLOGY MARKET SHARE, BY CANCER TYPE, (2021) (%)
FIGURE 161 APAC ONCOLOGY MARKET SHARE, BY CANCER CARE, (2021 V/S 2028) (%)
FIGURE 162 APAC INFECTIOUS DISEASES MARKET SHARE BY APPLICATION, (2021 V/S 2028) (%)
FIGURE 163 APAC BACTERIAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 164 APAC VIRAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 165 APAC FUNGAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 166 APAC OTHER INFECTIONS MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 167 APAC IVD MARKET SHARE, BY SAMPLE SOURCE, (2021 V/S 2028) (%)
FIGURE 168 APAC IVD MARKET SHARE, BY END-USERS, (2021 V/S 2028) (%)
FIGURE 169 APAC IVD MARKET SHARE, BY COUNTRY, (2021 V/S 2028) (%)
FIGURE 170 JAPAN IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
FIGURE 171 JAPAN IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
FIGURE 172 JAPAN IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
FIGURE 173 CHINA IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
FIGURE 174 CHINA IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
FIGURE 175 CHINA IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
FIGURE 176 INDIA IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
FIGURE 177 INDIA IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
FIGURE 178 INDIA IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
FIGURE 179 REST OF APAC IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
FIGURE 180 REST OF APAC IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
FIGURE 181 REST OF APAC IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
FIGURE 182 ROW IVD MARKET SHARE, BY PRODUCT, (2021 V/S 2028) (%)
FIGURE 183 ROW IVD MARKET SHARE, BY TECHNOLOGY, (2021 V/S 2028) (%)
FIGURE 184 ROW IMMUNOCHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 185 ROW CLINICAL CHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 186 ROW MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
FIGURE 187 ROW IVD MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
FIGURE 188 ROW ONCOLOGY MARKET SHARE, BY CANCER TYPE, (2021) (%)
FIGURE 189 ROW CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE, (2021 V/S 2028) (%)
FIGURE 190 ROW INFECTIOUS DISEASES MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
FIGURE 191 ROW BACTERIAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 192 ROW VIRAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 193 ROW FUNGAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 194 ROW OTHER INFECTIONS MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
FIGURE 195 ROW IVD MARKET SHARE, BY SAMPLE SOURCE, (2021 V/S 2028) (%)
FIGURE 196 ROW IVD MARKET SHARE, BY END-USERS, (2021 V/S 2028) (%)
FIGURE 197 ROW IVD MARKET SHARE, BY COUNTRY, (2021 V/S 2028) (%)
FIGURE 198 BRAZIL IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
FIGURE 199 BRAZIL IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
FIGURE 200 BRAZIL IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
FIGURE 201 REST OF LATAM IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
FIGURE 202 REST OF LATAM IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
FIGURE 203 REST OF LATIN AMERICA IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
FIGURE 204 MIDDLE EAST & OTHERS IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
FIGURE 205 MIDDLE EAST & OTHERS MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
FIGURE 206 MIDDLE EAST & OTHERS IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
FIGURE 207 KEY GROWTH STRATEGIES (2020-2021)
FIGURE 208 SWOT: ABBOTT LABORATORIES
FIGURE 209 SWOT: BIOMEREIEUX
FIGURE 210 SWOT: DANAHER CORPORATION
FIGURE 211 SWOT: DEXCOM INC.
FIGURE 212 SWOT: F. HOFFMANN LA ROCHE
FIGURE 213 SWOT: HOLOGIC, INC.
FIGURE 214 SWOT: QUIDEL CORPORATION
FIGURE 215 SWOT: SIEMENS HEALTHINEERS
FIGURE 216 SWOT: SYSMEX
FIGURE 217 SWOT: THERMO FISHER SCIENTIFIC